Vis enkel innførsel

dc.contributor.authorNielsen, Lene Kongsgaard
dc.contributor.authorStege, Claudia
dc.contributor.authorLissenberg-Witte, Birgit I.
dc.contributor.authorvan der Holt, Bronno
dc.contributor.authorMellqvist, Ulf-Henrik
dc.contributor.authorSalomo, Morten
dc.contributor.authorBos, Gerard
dc.contributor.authorLevin, Mark-David
dc.contributor.authorVisser-Wisselaar, Heleen
dc.contributor.authorHansson, Markus
dc.contributor.authorvan der Velden, Annette W.G.
dc.contributor.authorDeenik, Wendy
dc.contributor.authorCoenen, Juleon
dc.contributor.authorHinge, Maja
dc.contributor.authorKlein, Saskia K.
dc.contributor.authorTanis, Bea C.
dc.contributor.authorSzatkowski, Damian Lukasz
dc.contributor.authorBrouwer, Rolf E.
dc.contributor.authorWesterman, Matthijs
dc.contributor.authorLeys, Rineke
dc.contributor.authorSinnige, Harm A.M.
dc.contributor.authorHaukås, Einar
dc.contributor.authorvan der Hem, Klaas G.
dc.contributor.authorDurian, Marc F.
dc.contributor.authorGimsing, Peter
dc.contributor.authorvan de Donk, Niels
dc.contributor.authorSonneveld, Pieter
dc.contributor.authorWaage, Anders
dc.contributor.authorAbildgaard, Niels
dc.contributor.authorZweegman, Sonja
dc.date.accessioned2022-05-02T13:04:21Z
dc.date.available2022-05-02T13:04:21Z
dc.date.created2020-02-06T16:26:19Z
dc.date.issued2019
dc.identifier.issn0390-6078
dc.identifier.urihttps://hdl.handle.net/11250/2993669
dc.description.abstractData on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R). The EORTC QLQ-C30 and MY20 questionnaires were completed at baseline, after three and nine induction cycles and six and 12 months of maintenance therapy. Linear mixed models and minimal important differences were used for evaluation. 596 patients participated in HRQoL reporting. Patients reported clinically relevant improvement in global quality of life (QoL), future perspective and role and emotional functioning, and less fatigue and pain in both arms. The latter being of large effect size. In general, improvement occurred after 6–12 months of maintenance only and was independent of the World Health Organisation performance at baseline. Patients treated with MPR-R reported clinically relevant worsening of diarrhea, and patients treated with MPT-T reported a higher incidence of neuropathy. Patients who remained on lenalidomide maintenance therapy for at least three months reported clinically meaningful improvement in global QoL and role functioning at six months, remaining stable thereafter. There were no clinically meaningful deteriorations, but patients on thalidomide reported clinically relevant worsening in neuropathy. In general, HRQoL improves both during induction and maintenance therapy with immunomodulatory drugs. The side effect profile of treatment did not negatively affect global QoL, but it was, however, clinically relevant for the patients. (Clinicaltrials.gov identifier: NTR1630).en_US
dc.language.isoengen_US
dc.publisherFerrata Storti Foundationen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleHealth-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 studyen_US
dc.title.alternativeHealth-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.journalHaematologicaen_US
dc.identifier.doi10.3324/haematol.2019.222299
dc.identifier.cristin1791734
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal